Cargando…
The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
BACKGROUND: Activation of peroxisome proliferator-activated receptor (PPAR)gamma is associated with bone loss and increased fracture risk, while PPARalpha activation seems to have positive skeletal effects. To further explore these effects we have examined the effect of the PPARalpha agonists fenofi...
Autores principales: | Stunes, Astrid K, Westbroek, Irene, Gustafsson, Björn I, Fossmark, Reidar, Waarsing, Jan H, Eriksen, Erik F, Petzold, Christiane, Reseland, Janne E, Syversen, Unni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127763/ https://www.ncbi.nlm.nih.gov/pubmed/21615901 http://dx.doi.org/10.1186/1472-6823-11-11 |
Ejemplares similares
-
Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009) -
Skeletal Effects of the Saturated 3-Thia Fatty Acid Tetradecylthioacetic Acid in Rats
por: Stunes, Astrid Kamilla, et al.
Publicado: (2011) -
Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?
por: Aasarød, Kristin M., et al.
Publicado: (2021) -
The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
por: Swanson, Christine R, et al.
Publicado: (2011) -
In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer
por: Saidi, Samir A, et al.
Publicado: (2006)